
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Curadev Completes First Treatment Cycle in STING Agonist Trial
Details : CRD3874-SI targets STimulator of INterferon Genes to activate immune cells for tumor eradication and is being evaluated for sarcoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : Bayer AG
Deal Size : $270.4 million
Deal Type : Collaboration
Details : The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 23, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : Bayer AG
Deal Size : $270.4 million
Deal Type : Collaboration

Contact Us!